Dr. Koontz on Next Steps for Study of LHRH in Prostate Cancer

Bridget F. Koontz, MD
Published: Monday, Feb 19, 2018



Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses the next steps for the phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

This single-arm study was hypothesis generating, as many believe it would be interesting to look at a comparison with the current standard of care, explains Koontz. This study evaluated patients with aggressive cancer, but included higher-risk and intermediate patients. Investigators aimed to accrue patients who had localized but aggressive cancer so that there was no risk of metastatic disease, Koontz adds.

There are 2 current standards of care for these patients—intermediate-risk patients get 6 months of hormonal therapy, and the long-term patients get 2 years. Koontz believes it would be interesting to compare the outcome of this study with patients on those trials.

Additionally, physicians are investigating next-generation hormone actors, which is in line with the idea of having potent androgen blockade. This could sensitize cancer cells with radiation but limit the overall length of the hormone deprivation to maintain quality of life.


Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses the next steps for the phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

This single-arm study was hypothesis generating, as many believe it would be interesting to look at a comparison with the current standard of care, explains Koontz. This study evaluated patients with aggressive cancer, but included higher-risk and intermediate patients. Investigators aimed to accrue patients who had localized but aggressive cancer so that there was no risk of metastatic disease, Koontz adds.

There are 2 current standards of care for these patients—intermediate-risk patients get 6 months of hormonal therapy, and the long-term patients get 2 years. Koontz believes it would be interesting to compare the outcome of this study with patients on those trials.

Additionally, physicians are investigating next-generation hormone actors, which is in line with the idea of having potent androgen blockade. This could sensitize cancer cells with radiation but limit the overall length of the hormone deprivation to maintain quality of life.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x